Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type Apr 4, 2023 06:30AM
BitNile (NILE) to Change Name to Ault Alliance Dec 20, 2022 06:30AM
BitNile Holdings Plans to Change Name to Ault Alliance Dec 20, 2022 06:30AM
BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year’s Nine-Month Period Nov 21, 2022 07:27PM
BitNile (NILE) Reports Alzamend (ALZN) Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Nov 1, 2022 06:31AM


Nov 1, 2022 06:30AM BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (A
Aug 23, 2022 06:30AM BitNile Holdings Reports Second Quarter 2022 Financial Results
Apr 28, 2022 06:31AM BitNile (NILE) Makes Additional Investment in Alzamend Neuro (ALZN)
Apr 28, 2022 06:30AM BitNile Holdings Announces Additional Investment in Alzamend From Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Apr 18, 2022 06:31AM BitNile (NILE) Reports FY21 Revenue of $52.4M, Net Loss of $24.2M
Apr 18, 2022 06:30AM BitNile Holdings Reports 2021 Year-End Results
Nov 19, 2021 05:23PM Ault Global Holdings (DPW) Reports Q3 Negative Revenues of $30.8M, Net Loss of $42.9M
Nov 19, 2021 05:20PM Ault Global Holdings Reports Third Quarter 2021 Results
Nov 19, 2021 05:20PM CORRECTING and REPLACING Ault Global Holdings Reports Third Quarter 2021 Results